0001567619-18-007783.txt : 20181212 0001567619-18-007783.hdr.sgml : 20181212 20181212171249 ACCESSION NUMBER: 0001567619-18-007783 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181210 FILED AS OF DATE: 20181212 DATE AS OF CHANGE: 20181212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bilenker Joshua H. CENTRAL INDEX KEY: 0001612312 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 181231495 MAIL ADDRESS: STREET 1: C/O LOXO ONCOLOGY, INC. STREET 2: ONE LANDMARK SQUARE, SUITE 1122 CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 4 1 doc1.xml FORM 4 X0306 4 2018-12-10 0 0001581720 Loxo Oncology, Inc. LOXO 0001612312 Bilenker Joshua H. C/O LOXO ONCOLOGY, INC. ONE LANDMARK SQUARE, SUITE 1122 STAMFORD CT 06901 1 1 0 0 President & CEO Common Stock 2018-12-10 4 M 0 10000 13.67 A 174407 D Common Stock 2018-12-10 4 S 0 969 130.58 D 173438 D Common Stock 2018-12-10 4 S 0 2001 132.09 D 171437 D Common Stock 2018-12-10 4 S 0 2104 133.00 D 169333 D Common Stock 2018-12-10 4 S 0 2049 134.31 D 167284 D Common Stock 2018-12-10 4 S 0 2377 135.04 D 164907 D Common Stock 2018-12-10 4 S 0 400 136.48 D 164507 D Common Stock 2018-12-10 4 S 0 100 137.39 D 164407 D Common Stock 2018-12-11 4 M 0 10000 13.67 A 174407 D Common Stock 2018-12-11 4 S 0 647 134.63 D 173760 D Common Stock 2018-12-11 4 S 0 1153 135.76 D 172607 D Common Stock 2018-12-11 4 S 0 3393 136.79 D 169214 D Common Stock 2018-12-11 4 S 0 2407 137.63 D 166807 D Common Stock 2018-12-11 4 S 0 1100 139.05 D 165707 D Common Stock 2018-12-11 4 S 0 1200 140.15 D 164507 D Common Stock 2018-12-11 4 S 0 100 140.61 D 164407 D Common Stock 30000 I By Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 Employee Stock Option (Right to Buy) 13.67 2018-12-10 4 M 0 10000 0 D 2024-12-18 Common Stock 10000 328514 D Employee Stock Option (Right to Buy) 13.67 2018-12-11 4 M 0 10000 0 D 2024-12-18 Common Stock 10000 318514 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the aggregate of sales effected on the same day at different prices. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.14 to $131.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.48 to $132.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.56 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.91 to $134.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.91 to $135.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.28 to $135.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.30 to $136.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.31 to $137.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.32 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.53 to $139.40 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.59 to $140.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/Jennifer Burstein, by power of attorney 2018-12-12